ONCT - Oncternal and karolinska Institutet ink research deal for ROR1-targeting cell therapies

Clinical-stage biopharmaceutical company Oncternal Therapeutics (ONCT) has inked a research and development deal with Karolinska Institutet in Stockholm, Sweden, to advance novel ROR1-targeting cell therapies focused on CAR-T cells and CAR-NK (Natural Killer) cells from the laboratory into the clinic.As part of the deal, IND-supporting preclinical studies will be performed in the Cell and Gene Therapy Group within the NextGenNK Center, which is a Competence Center for the development of next-generation NK cell-based cancer immunotherapies."ROR1 has emerged as an important and underexplored target for cancer therapy," Oncternal’s President and CEO James Breitmeyer said."we believe that ROR1-targeting CAR-T and CAR-NK therapies hold significant promise for patients with both hematologic cancers and solid tumors," he added.

For further details see:

Oncternal and karolinska Institutet ink research deal for ROR1-targeting cell therapies